Analyzing...
Loading company...
Ami Organics Ltd. engages in the development and commercialization of pharmaceutical intermediate products. The company is headquartered in Surat, Gujarat and currently employs 561 full-time employees. The company went IPO on 2021-09-14. These specialty chemicals with varied end usage, focus on the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredient (APIs) and new chemical entity (NCEs). The company manufactures pharma intermediates for certain APIs, including dolutegravir, trazodone, entacapone, nintedanib and rivaroxaban. The pharma intermediates, which the Company manufactures have application in certain high-growth therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. The company has developed and commercialized over 450 pharma intermediates for APIs and NCEs across 17 therapeutic areas. Its specialty chemicals have applications in the agrochemicals and fine chemicals industries. The firm supplies its products to more than 150 customers directly in India.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,007 Cr revenue.
COGS 54.8%, employees 8.3%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.1%▲ | 10.3% |
| ROCE | 16.5%▲ | 13.7% |
| Net Margin | 15.5%▲ | 7.6% |
| EBITDA Margin | 24.3%▲ | 15.4% |
| Debt To Equity | 0.01x▼ | 0.15x |
| Rev Growth 3yr | 25.1%▲ | 10.0% |
| EPS Growth 3yr | 25.2%▲ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | ₹1,097 Cr +8.9% | ₹1,007 Cr +40.3% | ₹717 Cr +16.3% | ₹617 Cr +18.6% | ₹520 Cr |
| Other Income | ₹33 Cr +96.3% | ₹17 Cr +126.0% | ₹7 Cr +73.4% | ₹4 Cr +56.4% | ₹3 Cr |
| Total Income | ₹1,130 Cr +10.4% | ₹1,024 Cr +41.2% | ₹725 Cr +16.7% | ₹621 Cr +18.8% | ₹523 Cr |
| COGS | ₹543 Cr -1.7% | ₹552 Cr +34.1% | ₹412 Cr +24.4% | ₹331 Cr +21.3% | ₹273 Cr |
| ₹830 Cr +2.7% | ₹808 Cr +32.2% | ₹611 Cr +20.1% | ₹509 Cr +17.9% | ₹431 Cr | |
| Profit Before Tax | ₹300 Cr +39.0% | ₹216 Cr +163.9% | ₹82 Cr -27.0% | ₹112 Cr +22.7% | ₹91 Cr |
| ₹76 Cr +37.0% | ₹56 Cr +67.9% | ₹33 Cr +14.9% | ₹29 Cr +48.1% | ₹20 Cr | |
| Net Profit | ₹224 Cr +39.7% | ₹160 Cr +229.3% | ₹49 Cr -41.5% | ₹83 Cr +15.8% | ₹72 Cr |
| Profit (Owners) | ₹224 Cr +41.1% | ₹159 Cr +271.1% | ₹43 Cr -48.6% | ₹83 Cr +15.8% | ₹72 Cr |
| Minority Interest | ₹0.06 Cr -96.6% | ₹2 Cr -71.3% | ₹6 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹0.16 Cr) -19.1% | (₹0.14 Cr) +98.1% | (₹7 Cr) ↓ Decline | ₹3 Cr +62.4% | ₹2 Cr |
| EPS | ₹27.35 | ₹19.39 | ₹5.80 | ₹11.43 | ₹9.87 |
| Diluted Shares | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.